Research is also underway on the use of PARP-1 inhibitor in treatment other diseases, among others multiple sclerosis, rheumatoid arthritis, myocardial infarction, stroke, acute neuroinjury, and Parkinson’s disease [39,40]. Here, PARP1 is linked to myocardial infarction.